{"id":3065,"date":"2026-09-10T18:48:00","date_gmt":"2026-09-10T22:48:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3065"},"modified":"2026-09-12T10:40:57","modified_gmt":"2026-09-12T14:40:57","slug":"adjuvanted-cell-based-influenza-vaccine-meets-phase-3-objectives","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3065","title":{"rendered":"Adjuvanted Cell-Based Influenza Vaccine Meets Phase 3 Objectives"},"content":{"rendered":"

Evidence<\/strong> Peer-reviewed publication · Discovery<\/strong> September 11, 2026 · Importance<\/strong> 4\/5 · Direction<\/strong> Positive<\/p>\n

\"Adjuvanted<\/p>\n

Summary<\/h4>\n

A peer-reviewed Phase 3 study of CSL Seqirus’ MF59-adjuvanted, cell-derived, higher-dose quadrivalent influenza vaccine enrolled 7,699 adults aged 50 years or older across eight countries. The investigational vaccine was immunologically superior to an adjuvanted egg-based quadrivalent comparator across all four strains and assessed age groups. It was noninferior to a recombinant quadrivalent vaccine for three of four strains in adults 50 years or older and all four strains in those 65 or older. Antibody responses persisted through the season and safety was described as well tolerated. The trivalent formulation, Aujemflu, is approved in the United Kingdom and European Union for adults 50 or older. Immunogenicity does not establish superior prevention of influenza, hospitalization or death.<\/p>\n

What Happened<\/h4>\n

The randomized, observer-blind Celljuvant study NCT06015282 compared three lots of the investigational vaccine with licensed adjuvanted egg-based and recombinant quadrivalent vaccines, recruiting in Canada, Denmark, Estonia, Germany, Pakistan, the Philippines, the United Kingdom and the United States. The study evaluated immunogenicity, safety and manufacturing consistency, with a subset followed to one year. The product combines 45 micrograms of hemagglutinin per strain, MF59 adjuvant and cell-based antigen production. Most solicited reactions were reported as mild or moderate and resolved within three days. Exploratory neuraminidase-antibody responses were higher than with comparators, but the clinical contribution of those responses remains uncertain.<\/p>\n

Deep Analysis<\/h4>\n

Layered vaccine design improves breadth in older adults:<\/strong> Cell-based manufacturing can reduce egg-adaptive antigen changes, MF59 can broaden immune recruitment and higher antigen dose can offset immunosenescence. Consistent superiority versus the adjuvanted egg-based comparator supports a cumulative immunologic effect. Counterevidence is incomplete noninferiority against the recombinant comparator in the full 50-plus population and the absence of clinical-efficacy endpoints.<\/p>\n

A regulatory and policy bridge rather than a clinical endpoint win:<\/strong> The large randomized dataset and lot-consistency component are well suited to support licensing and immunization-policy review. However, hemagglutination-inhibition titers are an imperfect correlate in older adults, strain match varies by season and reactogenicity may affect uptake. Sustained responses and multi-technology design could matter when seasonal protection wanes, especially if effectiveness studies confirm fewer severe outcomes.<\/p>\n

Signal Extraction<\/h4>\n

Verified facts: randomized observer-blind Phase 3; 7,699 participants; eight countries; superiority versus adjuvanted egg-based vaccine across four strains; partial-to-complete noninferiority versus recombinant vaccine by age group; UK and EU approval of the trivalent formulation. Missing facts: exact geometric-mean titer ratios, adverse-event tables, clinical influenza endpoints and real-world effectiveness. Upgrade evidence would be replicated protection against laboratory-confirmed influenza, hospitalization and severe disease.<\/p>\n

Company and Product Background<\/h4>\n

CSL Seqirus is CSL’s influenza-vaccine business and operates manufacturing across the United States, United Kingdom and Australia. Aujemflu is the trivalent licensed formulation of the adjuvanted, cell-based, higher-dose platform for adults aged 50 years and older in the UK and EU.<\/p>\n

Older adults experience immunosenescence, comorbidity and higher influenza complication risk. Egg-based vaccine production can introduce antigenic adaptations. Cell culture aims to preserve closer antigen match, MF59 is an oil-in-water adjuvant that enhances immune activation, and increased hemagglutinin dose can raise antibody response. Combining all three adds manufacturing and cost complexity that must be justified by clinical and public-health value.<\/p>\n

InSilens Take<\/h4>\n

The trial validates a technically coherent combination of cell-based production, MF59 adjuvant and higher antigen dose at Phase 3 scale. Direction is positive for immunogenicity and regulatory readiness, but not yet for clinical superiority. The next decisive evidence is effectiveness against confirmed infection and severe outcomes across several seasons, with transparent comparison to recombinant and other enhanced vaccines in the populations most affected by immunosenescence.<\/p>\n

Signal Assessment<\/h4>\n\n\n\n\n\n
Signal Importance<\/strong><\/td>\n4 \/ 5 — a large randomized Phase 3 program supports a differentiated influenza platform already entering regulated markets<\/td>\n<\/tr>\n
Signal Direction<\/strong><\/td>\nPositive — immunogenicity objectives and disclosed tolerability were favorable; clinical-outcome superiority remains unproven<\/td>\n<\/tr>\n
Confidence in Facts<\/strong><\/td>\nHigh — the sponsor’s detailed disclosure is corroborated by the trial registry and licensed UK product information<\/td>\n<\/tr>\n
Confidence in Interpretation<\/strong><\/td>\nModerate — translation from immune response to seasonal clinical effectiveness, uptake and economics is unresolved<\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

A peer-reviewed Phase 3 study of CSL Seqirus’ MF59-adjuvanted, cell-derived, higher-dose quadrivalent influenza vaccine enrolled 7,699 adults aged 50 years or older across eight countries. The investigational vaccine was immunologically superior to an adjuvanted…<\/p>\n","protected":false},"author":1,"featured_media":3081,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,3],"tags":[703,706,702,704,705],"class_list":["post-3065","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical","category-therapeutic-indication","tag-aujemflu","tag-cell-based-vaccine","tag-csl-seqirus","tag-influenza-vaccine","tag-mf59-adjuvant"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3065","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3065"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3065\/revisions"}],"predecessor-version":[{"id":3083,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3065\/revisions\/3083"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3081"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3065"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3065"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3065"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}